Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India and internationally. More Details
Adequate balance sheet with moderate growth potential.
Share Price & News
How has Syngene International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 539268 has not had significant price volatility in the past 3 months.
7 Day Return
IN Life Sciences
1 Year Return
IN Life Sciences
Return vs Industry: 539268 matched the Indian Life Sciences industry which returned 61.9% over the past year.
Return vs Market: 539268 exceeded the Indian Market which returned 2.8% over the past year.
Price Volatility Vs. Market
How volatile is Syngene International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Is Syngene International undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 539268 (₹533.9) is trading above our estimate of fair value (₹92.63)
Significantly Below Fair Value: 539268 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 539268 is poor value based on its PE Ratio (59.9x) compared to the IN Life Sciences industry average (40.1x).
PE vs Market: 539268 is poor value based on its PE Ratio (59.9x) compared to the Indian market (16.5x).
Price to Earnings Growth Ratio
PEG Ratio: 539268 is poor value based on its PEG Ratio (2.4x)
Price to Book Ratio
PB vs Industry: 539268 is overvalued based on its PB Ratio (8.6x) compared to the IN Life Sciences industry average (1.8x).
How is Syngene International forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 539268's forecast earnings growth (25.3% per year) is above the savings rate (7.2%).
Earnings vs Market: 539268's earnings (25.3% per year) are forecast to grow slower than the Indian market (25.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 539268's revenue (19.1% per year) is forecast to grow faster than the Indian market (11.4% per year).
High Growth Revenue: 539268's revenue (19.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 539268's Return on Equity is forecast to be low in 3 years time (18.5%).
How has Syngene International performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 539268 has high quality earnings.
Growing Profit Margin: 539268's current net profit margins (17.1%) are lower than last year (20.5%).
Past Earnings Growth Analysis
Earnings Trend: 539268's earnings have grown by 12.1% per year over the past 5 years.
Accelerating Growth: 539268's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 539268 had negative earnings growth (-8.6%) over the past year, making it difficult to compare to the Life Sciences industry average (4.5%).
Return on Equity
High ROE: 539268's Return on Equity (14.4%) is considered low.
How is Syngene International's financial position?
Financial Position Analysis
Short Term Liabilities: 539268's short term assets (₹19.0B) exceed its short term liabilities (₹12.5B).
Long Term Liabilities: 539268's short term assets (₹19.0B) exceed its long term liabilities (₹7.8B).
Debt to Equity History and Analysis
Debt Level: 539268's debt to equity ratio (45.6%) is considered high.
Reducing Debt: 539268's debt to equity ratio has increased from 22.5% to 45.6% over the past 5 years.
Debt Coverage: 539268's debt is well covered by operating cash flow (56.3%).
Interest Coverage: 539268 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Syngene International current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 539268's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 539268's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 539268's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 539268's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 539268 is not paying a notable dividend for the Indian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 539268's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jonathan Hunt (51 yo)
Mr. Jonathan Brittan Hunt serves as the Managing Director of Syngene International Limited since April 1, 2020. He has been the Chief Executive Officer of Syngene International Ltd. since January 2016 and ...
CEO Compensation Analysis
Compensation vs Market: Jonathan's total compensation ($USD898.38K) is about average for companies of similar size in the Indian market ($USD775.42K).
Compensation vs Earnings: Jonathan's compensation has been consistent with company performance over the past year.
|MD, CEO & Executive Director||4.75yrs||₹66.32m||0.082% |
|Chief Financial Officer||0.83yr||₹34.14m||no data|
|Company Secretary & Compliance Officer||1.25yrs||₹4.72m||no data|
|Chief Operating Officer||1.25yrs||no data||no data|
|Head of Investor Relations||no data||no data||no data|
|Head of Corporate Communications||no data||no data||no data|
|Chief Human Resources Officer||0.75yr||no data||no data|
|Head of Pharmaceutical & Biopharmaceutical Development||no data||₹10.80m||0.010% |
|Head of Formulations Development||no data||₹5.50m||0.019% |
|Head of IT||4.67yrs||no data||no data|
|Head of Discovery Biology||4.75yrs||no data||no data|
|Head of Clinical Development & Stability Studies||4.75yrs||no data||no data|
Experienced Management: 539268's management team is considered experienced (3 years average tenure).
|MD, CEO & Executive Director||4.75yrs||₹66.32m||0.082% |
|Non-Executive Director||20.58yrs||₹1.87m||no data|
|Non-Executive Director||20.17yrs||₹3.35m||0.00053% |
|Non-Executive Chairperson||no data||no data||0.0089% |
|Non-Executive Independent Director||3.25yrs||₹2.84m||no data|
|Independent Director||3.58yrs||₹2.37m||0.013% |
|Non-Executive Independent Director||6.17yrs||₹3.85m||0.013% |
|Additional Independent Director||1yr||₹1.88m||no data|
|Additional Independent Director||1.17yrs||₹1.92m||no data|
Experienced Board: 539268's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 539268 insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Syngene International Limited's company bio, employee growth, exchange listings and data sources
- Name: Syngene International Limited
- Ticker: 539268
- Exchange: BSE
- Founded: 1993
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹211.711b
- Shares outstanding: 396.54m
- Website: https://www.syngeneintl.com
Number of Employees
- Syngene International Limited
- Biocon SEZ, Biocon Park,
- Plot No. 2 & 3
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|539268||BSE (Mumbai Stock Exchange)||Yes||Equity Shares||IN||INR||Aug 2015|
|SYNGENE||NSEI (National Stock Exchange of India)||Yes||Equity Shares||IN||INR||Aug 2015|
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India and internationally. The company offers discovery chemistry services, ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/25 12:35|
|End of Day Share Price||2020/10/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.